Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease

Hsin Hsiang Huang; Yun-Yi Chen; Yu-Wei Fang; Hung-Hsiang Liou; Jing-Tong Wang; Ming-Hsein Tsai

doi:10.12659/MSM.944314

12 June 2024 : Database Analysis

Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease

Hsin Hsiang Huang^1DE, Yun-Yi Chen^23BCD, Yu-Wei Fang^14ADG, Hung-Hsiang Liou^5AD, Jing-Tong Wang^1B, Ming-Hsein Tsai^14ADE*

DOI: 10.12659/MSM.944314

Med Sci Monit 2024; 30:e944314

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 4 Results of subgroup analysis performed to evaluate the outcomes of hospitalization for heart failure and hospitalization for cardiovascular intervention. (A) Hospitalization for heart failure. (B) Hospitalization for cardiovascular intervention. CHF – congestive heart failure; PVD – peripheral vascular disease; ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker; CCB – calcium channel blocker; NSAID – non-steroidal anti-inflammatory drug. The software used for creation of the figure: SAS (version 9.4; SAS Institute, Cary, NC, USA) and PowerPoint 2016 Microsoft.

Back to the Article

Comparative Cardiovascular Risks of Febuxostat and Allopurinol in Patients with Diabetes Mellitus and Chronic Kidney Disease

Your Privacy